AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03702582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
Study NCT03702582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
Study NCT03233490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web course
Description: Web course Help Brain Heart was conducted Before CPR training.
Study NCT03233490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR training
Description: No web course was conducted
Study NCT02932722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
Study NCT02932722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
Study NCT02932722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
Study NCT00255684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy
Study NCT00255684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00255684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00255684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00255684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00255684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT00255684 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03590262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: take the metformin 500mg twice or three times a day
Study NCT04006899 — intervention group
Intervention type: DEVICE
Intervention: Bioelectrical Impedance Monitor
Description: Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
Study NCT04066816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Participants will consume 2 ounces of walnuts for 21 days
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT00980408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 250 mg, one dose, 60 min prior
Study NCT00980408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 20 mg, one dose, 8 hours prior
Study NCT00980408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamic Acid
Description: 250 mg, one dose, 60 minutes prior
Study NCT00980408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 20 mg, one dose, 8 hours prior
Study NCT00650273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets 600 mg
Description: 600mg, single dose fasting
Study NCT00650273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® Tablets 600 mg
Description: 600mg, single dose fasting
Study NCT03077009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Ultrasound guided injection for plantaris friction syndrome
Study NCT02958930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MemorEM 1000
Description: The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
Study NCT01776528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Study NCT02751866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berry fruit powder OR nutritional ketosis
Description: Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
Study NCT02751866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder OR higher carbohydrate
Description: Daily supplementation with placebo powder OR higher carbohydrate intake
Study NCT04148690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group antenatal care (GANC)
Description: Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
Study NCT04148690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antenatal care
Description: Routine antenatal care as recommended by th Ministry of Health of Tanzania
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Human anti-PD-1 IgG4 kappa monoclonal antibody
Study NCT04424810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-quality, physician created video
Description: The intervention group will watch a short (2-5 minute) video prior to surgery that will provide them with information about their condition and the procedure they are about to undergo (either carpal tunnel release or trigger finger release).
Study NCT04424810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Patients in the control group will not be asked to do anything differently prior to their surgery
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters
Study NCT03169738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03169738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SRBT)
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL15N72D:IL-15RαSu/IgG1 Fc complex\]
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
Study NCT01598155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1 - Supragingival biofilm control
Description: 30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient.
Study NCT01598155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2 - Supra- and subgingival biofilm control
Description: 30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged.
Study NCT04694287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Percutaneous DUS volume flow measurements
Description: Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
Study NCT00901914 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sublingual tablet of matching placebo daily during approximately 5.5 months
Study NCT00901914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
Study NCT00901914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
Study NCT00901914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v 1
Description: One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
Study NCT01383876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collar
Description: Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
Study NCT01383876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Collar
Description: Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
Study NCT02772302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindBEAGLE EEG-based brain-computer interface
Study NCT03308279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound and Anthropometric meassures
Study NCT00863590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: \[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
Study NCT00863590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: odanacatib (Panel B)
Description: Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
Study NCT00863590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: odanacatib (Panel C)
Description: Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
Study NCT00863590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: odanacatib (Panel D)
Description: Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
Study NCT03662607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality experience
Description: * Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~* Seated comfortably and free of direct obstruction~* Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~* Begin the VR experience. Study personnel stay in the room \& provide guidance and answer questions regarding the technology~* When VR experience concluded, wellness self-assessment will be administered again.
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Ras yeast vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study NCT03169738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study NCT03542708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRP
Description: The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
Study NCT04330859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeoRehab Bundle
Description: The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
Study NCT04330859 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
Study NCT02697448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Participant receives propofol as anesthetic for cardiac ablation.
Study NCT02697448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: Participant receives sevoflurane as anesthetic for cardiac ablations.
Study NCT06511024 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
Study NCT03419780 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
Study NCT02507934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin
Description: Lubricin 150 µg/ml eye drops
Study NCT02507934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate 0.18% eye drops
Study NCT01265251 — intervention group
Intervention type: DEVICE
Intervention: Computerized neuropsychological test
Description: Computerized neuropsychological test battery.
Study NCT01265251 — intervention group
Intervention type: OTHER
Intervention: Conventional neuropsychological test
Description: Conventional neuropsychological test (paper and pen)
Study NCT03737604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Continuous Infusion Catheter
Description: For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
Study NCT03737604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Liposomal Bupivicaine
Description: TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
Study NCT01739114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPPV group
Description: Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided.
Study NCT01739114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SI group
Description: Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided
Study NCT02934958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colon Cancer Screening Navigation
Description: Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
Study NCT02934958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will be tracked to compare how effective are usual care methods
Study NCT01700569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
Study NCT01700569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid at pharmacological dose is the escalated drug
Study NCT01700569 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High voltage radiation therapy (linear accelerator)
Description: Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
Study NCT01106729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cyanidin 3 glucoside
Description: Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
Study NCT01594502 — intervention group
Intervention type: DRUG
Intervention: Dutasteride
Description: 0.5 mg daily
Study NCT01594502 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo Comparator
Study NCT03061344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DVIU treated with liquid buccal mucosal graft
Description: DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
Study NCT01744691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.